Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
One in two women with advanced ovarian cancer has an HRD-positive tumor
Philips FetView will offer real-time, off cart remote patient management with access to data from any ultrasound system
If implemented across the world, it has the capability to save over 100,000 lives annually
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
Daffodils by Artemis is a premiere luxury birthing centre offering mother and child care services.
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
Subscribe To Our Newsletter & Stay Updated
